Ian Degeling

Ian Degeling, as Co-Founder and Chief Technology Officer at SeraNovo B.V., plays a pivotal role in shaping the company's innovative trajectory within the pharmaceutical formulation landscape. His current role involves leading a highly skilled formulation team, fostering a culture of creativity, collaboration, and scientific excellence. Ian’s expertise in formulation science, combined with his deep knowledge of chemistry and eutectic systems, enables him to develop cutting-edge solutions that address complex drug delivery challenges.

At SeraNovo, Ian is responsible for defining and executing the company's technology strategy, ensuring that innovation remains at the core of its growth. His strategic vision emphasizes the integration of advanced R&D practices, leveraging his extensive research background to pioneer novel formulation techniques. A key project under his leadership includes the development of proprietary eutectic-based formulations, which have resulted in multiple patents and significantly improved bioavailability and stability of pharmaceutical compounds. These innovations not only enhance therapeutic efficacy but also streamline manufacturing processes, reducing costs and time-to-market.

Ian’s passion for advancing formulation science is evident in his role as a co-inventor of SeraNovo’s core technology platform. His commitment to pushing the boundaries of pharmaceutical formulation has positioned SeraNovo as a leader in the field, with a focus on delivering scalable, patentable solutions that meet the evolving needs of the industry. Through his strategic oversight and technical expertise, Ian continues to drive SeraNovo’s evolution, ensuring the company remains at the forefront of formulation innovation and pharmaceutical development.